SEC Form 4 · accession 0001140361-26-029817
Lyell Immunopharma, Inc. · LYEL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Period of report
Jul 27, 2026
Accepted (ET)
Jul 27, 2026 · 9:14 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001806952
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jul 27, 2026 | J | 44,000 | $0.00 | D | 2,774,980 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares of Common Stock transferred by the Reporting Person to Wuxiong, Inc. as broker commission in connection with the first Development Milestone payment (as defined in Section 6.2(a) of the License Agreement, dated November 6, 2025, between the Issuer and the Reporting Person). The transaction was a transfer of securities for no cash consideration to the Reporting Person and is reported under transaction code J.
- F2Reflects 2,818,980 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 44,000 shares transferred.